Charles Schwab Investment Management Inc Pyxis Oncology, Inc. Transaction History
Charles Schwab Investment Management Inc
- $521 Billion
- Q1 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Pyxis Oncology, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 115,237 shares of PYXS stock, worth $154,417. This represents 0.0% of its overall portfolio holdings.
Number of Shares
115,237
Previous 129,761
11.19%
Holding current value
$154,417
Previous $201,000
44.28%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding PYXS
# of Institutions
90Shares Held
23.2MCall Options Held
138KPut Options Held
30.9K-
Laurion Capital Management LP New York, NY3.63MShares$4.86 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.79MShares$3.73 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.49MShares$3.33 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.44MShares$3.27 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.11MShares$1.49 Million0.0% of portfolio
About Pyxis Oncology, Inc.
- Ticker PYXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,096,400
- Market Cap $47M
- Description
- Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...